David Cameron is apparently about to announce that private companies – i.e., pharmaceutical companies – will be able to access NHS patient data. Over the last couple of years, I have had concerns that the opt-out system into electronic medical records is wrong, and should instead be an opt-in system. I’ve been concerned that the kind of […]
Continue Reading →Libel debate in Prometheus
A series of articles about the dreadful state of Libel Law in the UK. Lots to read: Peter Wilmshurst, John Garrow, me, David Colquhoun. Free to access till end of September.
Continue Reading →Preventative measures for breast cancer, and how we view risk
The Lancet has run a Consensus Statement about preventing breast cancer. They say “Many risk factors have been established for breast cancer, the most informative of which are family history of the disease, especially at a young age, increased mammographic breast density, some menstrual and reproductive factors, and proliferative benign disease. Various models have been […]
Continue Reading →Healthcare charities and the uselessness of GPs (again)
..and so, again and again, that GPs are in some way ‘undertrained’. We aren’t specialists – we are generalists. It’s a different job, with different skills. But it’s a myth to repeat that just because a GPs doesn’t have specialist training somehow means that the doctor is incompetent or lacking in training. GP training consists […]
Continue Reading →Peter Wilmshurst, free speech and libel
An article in TheHeart.org – Dr Wilmshurst is now being threatened with libel over a radio interview he did a year ago. I interviewed Dr Wilmshurst for the FT at around the same time. It was a shortish interview, discussing the reasons why he’d spoken out about the research he’d been involved with and the […]
Continue Reading →The myth of the male menopause
….an article at the BMJ, toll free here
Continue Reading →Andrew Lansley’s big mistake
NICE is not perfect. It never has been. It has, though, been a good start at trying to examine evidence and come to a fair and equitable decision as to what healthcare interventions to publically fund. NICE has faults. It has become a bit too easy on lobbyists – especially health care charity lobbyists – […]
Continue Reading →Carl Elliott on opinion leaders
Excellent article. Looking forward to reading his book.
Continue Reading →Avastin and cost effectiveness
I can’t understand the blame being apportioned in press coverage over NICE’s decision not to fund Avastin, or bevacizumab, for the treatment of advanced bowel cancer. Many patients groups are laying the blame with NICE. Is this fair? The important bit to me is ‘cost effectiveness’. It isn’t about either cost or effectiveness alone. While […]
Continue Reading →Is your doctor a ‘high flyer’ or a ‘rule bound’?
The latest on AstraZeneca, who are having to pay 198 million US dollars to patients who have developed diabetes on the anti psychotic drug quetiapine is only one bit of a long story. The challenge being made is that the weight gain and tendency to diabetes for some patients was known by AstraZeneca but not acknowledged fully on the […]
Continue Reading →